News

Impact of Age on Quality of Life After Immune Checkpoint Inhibitor Treatment for Patients With Lung Cancer

02/07/2023

Derek Cowsert

A study found old age to be a significant risk factor for lower quality of life scores for patients with lung cancer who received immune checkpoint inhibitor treatment.

A study found old age to be a...

02/07/2023

Oncology

News

FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

01/27/2023

On January 26, 2023, the FDA granted approval to pembrolizumab as an adjuvant treatment for patients with non-small cell lung cancer.

On January 26, 2023, the FDA...

01/27/2023

Oncology

News

Lorlatinib Significantly Improves Survival vs Crizotinib in Patients With ALK-Positive Advanced NSCLC Regardless of Brain Metastases

07/12/2022

Derek Cowsert

Lorlatinib was associated with improved PFS vs crizotinib among patients with ALK-positive advanced NSCLC, with or without brain metastases, according to findings from the phase 3 CROWN study.

Lorlatinib was associated with...

07/12/2022

Oncology

News

Amivantamab Associated With Improved Outcomes vs Real-World Therapies in EGFR-Mutated NSCLC

07/07/2022

Janelle Bradley

Among patients with EGFR-mutated advanced NSCLC whose disease progressed after platinum-based chemotherapy, treatment with amivantamab is associated with improved outcomes vs real-world therapies, according to a recent study.

Among patients with EGFR-mutated...

07/07/2022

Oncology

News

Tazemetostat Reduces EZH2 Activity in Patients with Malignant Mesothelioma

07/06/2022

Derek Cowsert

Findings from an open-label phase 2 study reveal treatment with tazemetostat reduces EZH2 activity and B-cell infiltration in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.

Findings from an open-label...

07/06/2022

Oncology

News

Adagrasib Demonstrates Clinical Efficacy, Safety in KRAS-Mutated NSCLC

07/06/2022

Derek Cowsert

Findings from a phase 2 trial show promising efficacy and safety with adagrasib for patients with KRAS-mutated NSCLC.

Findings from a phase 2 trial...

07/06/2022

Oncology

News

Driver Variations Associated With Shorter PFS in Patients With NSCLC Receiving Chemoradiation and Durvalumab

07/06/2022

Derek Cowsert

A phase 3 cohort study identified driver variations associated with shorter PFS among patients with NSCLC receiving definitive chemoradiation and consolidative durvalumab, highlighting the need for alternative treatment options for these...

A phase 3 cohort study...

07/06/2022

Oncology

News

Tiragolumab Plus Atezolizumab Improves PFS vs Placebo Plus Atezolizumab in NSCLC: CITYSCAPE Trial

07/05/2022

Derek Cowsert

Tiragolumab plus atezolizumab yielded improved objective response rates and PFS vs placebo plus atezolizumab as first-line treatment for patients with NSCLC in the phase 2 CITYSCAPE trial.

Tiragolumab plus atezolizumab...

07/05/2022

Oncology

News

Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status

06/28/2022

Hina M. Porcelli

Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.

Findings from a systematic...

06/28/2022

Oncology

News

Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status

06/28/2022

Hina M. Porcelli

Findings from a systematic...

06/28/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology